| Literature DB >> 31295880 |
Mariana Margatto Rottini1, Ana Claudia Fernandes Amaral2, José Luiz Pinto Ferreira2, Edinilze Souza Coelho Oliveira3, Jefferson Rocha de Andrade Silva3, Noemi Nosomi Taniwaki4, Arith Ramos Dos Santos2, Fernando Almeida-Souza1,5, Celeste da Silva Freitas de Souza1, Kátia da Silva Calabrese6.
Abstract
The difficulties encountered and the numerous side effects present in the treatment of cutaneous leishmaniasis have encouraged the research for new compounds that can complement or replace existing treatment. The growing scientific interest in the study of plants, which are already used in folk remedies, has led our group to test Endlicheria bracteolata essential oil against Leishmania amazonensis. Several species of the Lauraceae family, or their compounds, have relevant antiprotozoal activities Therefore, the biological potential on L. amazonensis forms from the essential oil of Endlicheria bracteolata leaves was verified for the first time in that work. The antileishmanial activity was evaluated against promastigotes and intracellular amastigotes, and cytotoxicity were performed with J774.G8, which were incubated with different concentrations of E. bracteolata essential oil. Transmission electron microscopy and flow cytometry were performed with E. bracteolata essential oil IC50. Promastigote forms showed E. bracteolata essential oil IC50 of 7.945 ± 1.285 µg/mL (24 h) and 6.186 ± 1.226 µg/mL (48 h), while for intracellular amastigote forms it was 3.546 ± 1.184 µg/mL (24 h). The CC50 was 15.14 ± 0.090 µg/mL showing that E. bracteolata essential oil is less toxic to macrophages than to parasites. Transmission electron microscopy showed that E. bracteolata essential oil treatment is capable of inducing mitochondrial damage to promastigote and intracellular amastigote forms, while flow cytometry showed ΔѰm disruption in treated parasites. These results could bring about new possibilities to develop products based on E. bracteolata essential oil to treat cutaneous leishmaniasis, especially for people who cannot receive the conventional therapy.Entities:
Keywords: cytotoxicity; essential oil; leishmanicidal activity; transmission electron microscopy
Year: 2019 PMID: 31295880 PMCID: PMC6680765 DOI: 10.3390/molecules24142525
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Chemical composition of the Endlicheria bracteolata essential oil.
| Compounds | Retention Index | Total Area (%) |
|---|---|---|
|
| ||
| α-thujene | 930 | 0.1 |
| α-pinene | 939 | 1.1 |
| β-pinene | 979 | 0.7 |
| myrcene | 990 | 0.1 |
| α-phellandrene | 1002 | 3.4 |
| ρ-cymene | 1024 | 2.0 |
| limonene | 1029 | 0.3 |
|
| ||
| α-copaene | 1376 | 0.2 |
| β-elemene | 1390 | 0.5 |
| (E)-caryophyllene | 1419 | 3.8 |
| β-gurjunene | 1433 | 0.3 |
| γ-elemene | 1436 | 0.2 |
| α-guaiene | 1438 | 0.6 |
| aromadendrene | 1441 | 0.2 |
| premnaspirodiene | 1451 | 0.2 |
| β-selinene | 1490 | 1.1 |
| δ-selinene | 1492 | 0.1 |
| viridiflorene | 1496 | 0.1 |
| Isodaucene | 1499 | 0.5 |
| α-muurolene | 1500 | 0.2 |
| α-bulnesene | 1509 | 1.3 |
| δ-cadinene | 1523 | 0.1 |
| selina-3,7(11)diene | 1546 | 0.1 |
| rosifoliol | 1548 | 0.6 |
| elemol | 1549 | 2.6 |
| occidentalol | 1552 | 0.1 |
| germacrene B | 1561 | 3.0 |
| guaiol | 1600 | 46.4 |
| 10-epi- γ-eudesmol | 1622 | 17.9 |
| γ-eudesmol | 1632 | 1.0 |
| α-eudesmol | 1653 | 1.2 |
| α-cadinol | 1654 | 0.1 |
| bulnesol | 1671 | 3.7 |
|
| ||
| Monoterpenes | 7.7 | |
| Hydrocarbon sesquiterpenes | 12.5 | |
| Oxygenated sesquiterpenes | 73.6 | |
|
| 93.8 |
Figure 1Effects of Endlicheria bracteolata essential oil on growth inhibition of Leishmania amazonensis promastigote forms. Data represents the mean ± error of three independent experiments carried out in triplicate. * p = 0.0168 when compared concentration treatment at different times by two-way ANOVA and Bonferroni’s multiple comparisons test.
Antileishmanial activity, cytotoxicity and selectivity index of Endlicheria bracteolata essential oil for 24 hours of treatment.
| Compounds | J774.G8 | SI | ||
|---|---|---|---|---|
| Promastigote | Intracelular Amastigote | |||
|
| 7.945 ± 1.285 | 3.546 ± 1.184 | 15.14 ± 0.090 | 4.27 |
| Amphotericin B | 1.521 ± 1.500 | 0.869 ± 0.774 | 19.97 ± 1.462 | 22.9 |
IC50: inhibitory concentration for 50% of parasites; CC50: cytotoxic concentration for 50% of cells; SI: selectivity index, obtained from ratio CC50/IC50 intracellular amastigote. Data represents mean ± standard deviation of three independent experiments carried out in triplicate.
Figure 2Light microscopy of Leishmania amazonensis intracellular amastigotes in J774.G8 macrophages. (A) L. amazonensis infected non-treated cells showing numerous internalized amastigotes (arrow). (B) L. amazonensis infected cells treated with 7.93 µg/mL of Endlicheria bracteolata essential oil against showing few amastigotes (arrow). Giemsa.
Figure 3Intracellular amastigotes number of J774.G8 macrophages treated with Endlicheria bracteolata essential oil for 24 h. Each column represents the mean number of intracellular amastigotes in cell cultures treated with different concentrations of E. bracteolata essential oil. The value represents the number of amastigotes counted in 100 cells in three independent experiments carried out in duplicate. * p < 0.05; ** p < 0.01; *** p < 0.001 when compared to untreated cells by Kruskal-Wallis and Dunn’s multiple comparisons test.
Figure 4Transmission electron microscopy of Leishmania amazonensis promastigote forms treated for different times with Endlicheria bracteolata (7.93 μg/mL). (A) Untreated parasites showing the characteristic structure of kinetoplastids (K), flagellar pocket (FP), and nucleus (N). (B) Promastigotes treated for 2 h showing electron-dense structures (arrowhead), in the box above note the presence of multivesicles (arrow), mitochondrial swelling (M) and presence of lipid droplets (L). (C) 4 h of treatment showing kinetoplast swelling (K), increased number of lipid droplets (L) and electron-dense structures (arrowhead). (D) 8 h of treatment showing large lipid droplets close to the plasma membrane (L) and discontinuity of the plasma membrane (asterisk). (E) 16 h of treatment showing kinetoplast swelling (K), lipid droplets (L) and multivesicles inside the flagellar pocket (FP) (arrow). (F) promastigotes after 24h of treatment showing increased volume of the kinetoplast (K), increased number of lipid droplets (L) and electron-dense structures (arrowheads).
Figure 5Ultrastructural effects of Endlicheria bracteolata essential oil on intracellular Leishmania amazonensis amastigotes and macrophage cells. (A) Untreated and uninfected macrophages showing typical morphology; (B) macrophages treated for 24h also showing typical morphology; (C) infected macrophages showing intact kinetoplast in the amastigote forms; (D) Infected and treated macrophages showing ultrastructural changes in the amastigotes such as the presence of vacuoles (arrows) in the cytoplasm and damage to their mitochondria (M). No changes were observed in the morphology of the host cell. N: nucleus; M: mitochondria; K: kinetoplast; Pv: parasitophorous vacuole.
Figure 6Flow cytometry of Leishmania amazonensis treated with 7.93 µg/mL of Endlicheria bracteolata essential oil to evaluate the mitochondrial membrane potential (ΔѰm). (A) Promastigotes captured in the gated region. (B–G) representative histograms of non-treated promastigotes incubated with TMRE showing ΔѰm intact in R2 and change of ΔѰm in R3. Promastigotes untreated (B) and treated for 2 h (C), 4 h (D), 8 h (E), 16 h (F), and 24 h (G).